Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock

Novo Nordisk (NVO), a key player in the diabetes and obesity markets, is highlighted as a stock to watch by Zacks, possessing a Zacks Rank of #3 (Hold). NVO exhibits strong momentum, with shares up 9% in the last four weeks and a Momentum Style Score of A; the consensus EPS estimate for fiscal year 2025 has increased by $0.07 to $3.87 per share based on upward revisions from four analysts.

Analysis

Novo Nordisk (NVO), a global healthcare company prominent in the diabetes and obesity markets, currently holds a Zacks Rank #3 (Hold). Despite this neutral rating, NVO exhibits strong momentum characteristics, evidenced by a Momentum Style Score of 'A' and a 9% increase in its share price over the past four weeks. This positive momentum is complemented by an improving earnings outlook; for fiscal year 2025, four analysts have revised their earnings per share (EPS) estimates upwards in the last 60 days, resulting in the Zacks Consensus Estimate rising by $0.07 to $3.87 per share. Furthermore, NVO scores a 'B' on the VGM (Value, Growth, Momentum) Style Score, indicating a favorable overall profile. While the company has an average earnings surprise of 0%, the combination of its Hold rank with strong Style Scores suggests, according to the Zacks methodology, that NVO could still present upside potential and warrants consideration by investors.

Key Decisions for Investors

• Investors should weigh NVO's strong recent price momentum and positive fiscal 2025 earnings estimate revisions against its current Zacks #3 (Hold) rating when evaluating the stock.
• Given its 'A' Momentum Style Score and 'B' VGM score, NVO may be of particular interest to momentum-oriented investors or those seeking stocks with a balanced style profile, meriting a place on their watchlist.
• Monitor upcoming earnings reports and further analyst estimate revisions closely, as sustained positive trends could signal a potential improvement in the stock's fundamental outlook and Zacks Rank.